Palisade Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-2.9%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$0.24next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Phase 2 Primary Efficacy Readout of PALI-2108 for Ulcerative Colitis (UC) | 31 Dec 2027 |
| Phase 2 Primary Efficacy Readout of PALI-2108 for Fibrostenotic Crohn's Disease (FSCD) | 31 Mar 2028 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly132.6MTarget: Sufficient to fund operations through major clinical development milestones, including Phase 2 readouts
Research and Development (R&D) Expenses Quarterly6.4MTarget: Reflective of escalating clinical and CMC activities for PALI-2108
Watch Items
- PALI-2108 Phase 2 IND Submission for Ulcerative Colitis (UC)Trigger: Submission and FDA clearance of the IND applicationAction: Initiate Phase 2 clinical trial dosing for UC patients
- PALI-2108 Phase 2 IND Submission for Fibrostenotic Crohn's Disease (FSCD)Trigger: Submission and FDA clearance of the IND applicationAction: Initiate Phase 2 clinical trial dosing for FSCD patients
Research as of 20 Jun 2026